The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      a Centre for Health Economics, University of York, Heslington, North Yorkshire YO10 5DD, United Kingdom
      b Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham NG7 2UH, United Kingdom
      c SHORE-C, University of Sussex, Brighton BN1 9RX, United Kingdom
      d Brighton and Sussex University Hospitals, Brighton BN2 5DA, United Kingdom
    • Keywords:
      Breast cancer
      Gene expression
      Economic evaluation
      Cost-effectiveness
      EndoPredict
      Risk of recurrence
    • Abstract:
      Highlights •Few studies have explored the role of EndoPredict in the treatment of breast cancer.•This study considers the role of EndoPredict in an indeterminate risk treatment group.•EndoPredict is expected to not be cost-effective but with significant uncertainty.
    • Abstract:
      Methods This study evaluated the cost-effectiveness of EndoPredict in patients with indeterminate risk classification. A mathematical model was constructed to determine how the change in treatment decisions impacted the long term health of the population, and the future cost implications to the NHS.
    • Abstract:
      Results EndoPredict was found to lead to 36.9% of patients having a change in treatment decision. As a result its use was found to result in an increase in population health but also in total costs, resulting in an incremental cost-effectiveness ratio of £26,836 per quality adjusted life year. This was subject to significant parametric and structural uncertainty.
    • Abstract:
      Conclusion While EndoPredict was found to be more expensive overall, its ability to affect a more optimal allocation of chemotherapy, resulted in long term health gains, however, they were insufficient to justify the high cost of EndoPredict.
    • ISSN:
      2211-8837
    • Accession Number:
      10.1016/j.hlpt.2018.12.001
    • Accession Number:
      S2211883718301977
    • Copyright:
      © 2019 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. All rights reserved.
  • Citations
    • ABNT:
      HINDE, S. et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology, [s. l.], 2018. DOI 10.1016/j.hlpt.2018.12.001. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S2211883718301977. Acesso em: 20 out. 2020.
    • AMA:
      Hinde S, Theriou C, May S, et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology. January 2018. doi:10.1016/j.hlpt.2018.12.001
    • APA:
      Hinde, S., Theriou, C., May, S., Matthews, L., Arbon, A., Fallowfield, L., & Bloomfield, D. (2018). The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology. https://doi.org/10.1016/j.hlpt.2018.12.001
    • Chicago/Turabian: Author-Date:
      Hinde, Sebastian, Chloi Theriou, Shirley May, Lucy Matthews, Amy Arbon, Lesley Fallowfield, and David Bloomfield. 2018. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy and Technology, January. doi:10.1016/j.hlpt.2018.12.001.
    • Harvard:
      Hinde, S. et al. (2018) ‘The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Health Policy and Technology. doi: 10.1016/j.hlpt.2018.12.001.
    • Harvard: Australian:
      Hinde, S, Theriou, C, May, S, Matthews, L, Arbon, A, Fallowfield, L & Bloomfield, D 2018, ‘The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Health Policy and Technology, viewed 20 October 2020, .
    • MLA:
      Hinde, Sebastian, et al. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy and Technology, Jan. 2018. EBSCOhost, doi:10.1016/j.hlpt.2018.12.001.
    • Chicago/Turabian: Humanities:
      Hinde, Sebastian, Chloi Theriou, Shirley May, Lucy Matthews, Amy Arbon, Lesley Fallowfield, and David Bloomfield. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy and Technology, January 1, 2018. doi:10.1016/j.hlpt.2018.12.001.
    • Vancouver/ICMJE:
      Hinde S, Theriou C, May S, Matthews L, Arbon A, Fallowfield L, et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology [Internet]. 2018 Jan 1 [cited 2020 Oct 20]; Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S2211883718301977